The Molecular Glue Drug Development Summit returns to Boston with fresh insights and opportunities! With powerhouse partnerships lighting up the industry—like Biogen & Neomorph, Inc.’s groundbreaking ...
Don’t stop Monte Rosa Therapeutics now. The Boston-based biotech is having a ball after signing a deal with Novartis to the tune of $150 million for a molecular glue degrader, developed using the ...
“Apparently, nail glue reacts with cotton and wool and causes ... Thankfully, the friend’s mother was nearby and quickly jumped into action, cutting off the sock and rinsing off the burn ...
(NASDAQ:GLUE) was able to establish a partnership deal ... This data will be important to see if the mechanism of action [MOA] of MRT-6160 can achieve its goal of VAV1 protein degradation.